Slowing Tecfidera Sales Increases Biogen's (BIIB) M&A Risk - Moody's

Moody's Investors Service commented that slowing sales of Tecfidera, the largest product of Biogen (NASDAQ: BIIB) increases the event risk of acquisitions. That said, there is currently no effect on Biogen's Baa1 senior unsecured rating or stable rating outlook based on strong financial flexibility.

You May Also Be Interested In

• Biogen (BIIB) PT Lowered to $270 at Oppenheimer
• Fiserv (FI) PT Raised to $175 at TD Cowen
• Moody's Raises Meta Platforms' (META) Senior Unsecured Notes Rating to Aa3 From A1